SCHEMBL23328981

SCHEMBL23328981

Cc1cnnn1-c1ccc(C(C)C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.56
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
NOTUM Q6P988 2/20 0.51
ALDH1A1 P00352 3/20 0.50
MAPT P10636 3/20 0.50
HPGD P15428 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
FLT3 P36888 2/20 0.42
DHODH Q02127 1/20 0.41
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PKM P14618 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
HTT P42858 1/20 0.39
MGLL Q99685 1/20 0.39
NPBWR1 P48145 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760260 0.81 TSHR (0.59) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL1500290 0.76 TSHR (0.58) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL23329191 0.74 TSHR (0.56) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL18865728 0.73 TSHR (0.54) TSHRMEN1KMT2ANOTUMALDH1A1
SCHEMBL18865730 0.73 TSHR (0.54) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL24469923 0.73 TSHR (0.58) TSHRMEN1KMT2AALDH1A1MAPT
SCHEMBL22020816 0.70 ALDH1A1 (0.56) NOTUMALDH1A1MAPTHPGDLMNA
SCHEMBL10022371 0.70 LMNA (0.51) MEN1KMT2ANOTUMALDH1A1MAPT
SCHEMBL24185357 0.69 TSHR (0.50) TSHRMEN1KMT2ANOTUMALDH1A1
SCHEMBL22924531 0.69 NPBWR1 (0.44) NOTUMALDH1A1LMNASMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO TSHR 2776/4885MEN1 4787/4885KMT2A 4246/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO TSHR 2776/4885MEN1 4787/4885KMT2A 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.